Clinical Trials Browser

Phase 1/2 × pembrolizumab × 30 days × Clear all

NCT07302347 2026-04-17

MK-3475-G21

Phase 1/2 Recruiting

DermatologicLymphoid

Lymphoma, Neoplasms, Carcinoma, Merkel Cell

NCT04219254 2026-04-15

A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor, Adult

NCT07213934 2026-04-15

Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma

Phase 1/2 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03786081 2026-04-14

Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer

Phase 1/2 Terminated

Uterine Cervical Neoplasms

NCT05232851 2026-04-14

A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer

Phase 1/2 Active not recruiting

20 enrolled 11 charts

Carcinoma, Oropharyngeal Neoplasms

NCT06470763 2026-04-14

EXPAND-1

Phase 1/2 Active not recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT03854474 2026-04-13

Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma

Phase 1/2 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04216316 2026-04-13

Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer

Phase 1/2 Active not recruiting

12 enrolled 25 charts

Lung Neoplasms

NCT04799054 2026-04-13

A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors

Phase 1/2 Terminated

Neoplasm Metastasis

NCT04938817 2026-04-13

KEYNOTE-B98

Phase 1/2 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT06385080 2026-04-13

OrigAMI-4

Phase 1/2 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT06469944 2026-04-13

MK-3475-06C

Phase 1/2 Recruiting

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT07223047 2026-04-13

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

Phase 1/2 Recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT07232602 2026-04-13

MK-3475-04D

Phase 1/2 Recruiting

Urinary Bladder Neoplasms

NCT03277638 2026-04-09

Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)

Phase 1/2 Active not recruiting

Brain Neoplasms, Glioblastoma

NCT06253494 2026-04-09

Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

Phase 1/2 Recruiting

Endometrial Neoplasms

NCT04083599 2026-04-08

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

Phase 1/2 Active not recruiting

DermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

NCT04305054 2026-04-08

KEYMAKER-U02

Phase 1/2 Active not recruiting

Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT04420884 2026-04-08

iintune-1

Phase 1/2 Completed

Solid Neoplasms

NCT05083481 2026-04-08

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

Phase 1/2 Active not recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT07262619 2026-04-08

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

Phase 1/2 Recruiting

Turcot syndrome, Neoplasm Metastasis, Endometrial Neoplasms

NCT05579366 2026-04-07

RAINFOL-01

Phase 1/2 Recruiting

BreastGynecologicOther solid neoplasmThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Fallopian Tube Neoplasms, Mesothelioma, Ovarian Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03917381 2026-04-06

GEN1046 Safety Trial in Patients With Malignant Solid Tumors

Phase 1/2 Active not recruiting

Other solid neoplasm

Solid Tumors

NCT05440708 2026-04-06

A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

Phase 1/2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT05732831 2026-04-06

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

Phase 1/2 Recruiting

GastrointestinalOther solid neoplasmSarcomaThoracic

Mesothelioma, Sarcoma, Cholangiocarcinoma, Neurofibrosarcoma

NCT05920798 2026-04-06

FRAPPE

Phase 1/2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05533697 2026-04-03

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

Neoplasm Metastasis, Neoplasms, Recurrence

NCT06116136 2026-04-03

A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.

Phase 1/2 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT07020221 2026-04-03

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Phase 1/2 Recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT05562830 2026-04-02

MK-3475-04A

Phase 1/2 Active not recruiting

Carcinoma, Transitional Cell

NCT03126630 2026-04-01

Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma

Phase 1/2 Active not recruiting

49 enrolled 20 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT07287995 2026-04-01

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

Phase 1/2 Recruiting

BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT06780111 2026-03-31

MK-3475-06E

Phase 1/2 Recruiting

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT03449238 2026-03-30

Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients

Phase 1/2 Recruiting

Brain Neoplasms, Breast Neoplasms

NCT03983668 2026-03-30

CMP-001 for Relapsed and Refractory Lymphoma

Phase 1/2 Terminated

14 enrolled 11 charts

Lymphoma

NCT06843447 2026-03-27

MK-5909-003

Phase 1/2 Recruiting

Ovarian Cancer Recurrent

NCT03288545 2026-03-24

EV-103

Phase 1/2 Terminated

348 enrolled 2 FDA

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

NCT05849480 2026-03-24

A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)

Phase 1/2 Recruiting

Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms

NCT05319730 2026-03-20

MK-3475-06B

Phase 1/2 Recruiting

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms